These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7020064)

  • 1. The use of an angiotensin II antagonist (saralasin) as an adjunct during renal vein catheterization.
    Ibsen H; Giese J; Rabøl A; Kappelgaard AM
    Scand J Clin Lab Invest; 1980 Apr; 40(2):115-20. PubMed ID: 7020064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of saralasin on blood pressure, renin and renal blood flow in unilateral renovascular hypertension.
    Arlart IP; Rosenthal J; Wagner H; Adam WE; Nobbe F; Franz HE
    Contrib Nephrol; 1978; 11():170-4. PubMed ID: 699587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of saralasin on normal blood pressure and on reno-vascular hypertension (author's transl)].
    Beckerhoff R; Vetter W; Furrer J; Nussberger J; Schmied U; Siegenthaler W
    Dtsch Med Wochenschr; 1976 Mar; 101(11):398-401. PubMed ID: 1253700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Saralasin test, renal vein renin and unilateral kidney blood flow in renovascular hypertension].
    Helber A; Hummerich W; Bönner G; Meurer KA; Moritz G
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():208-9. PubMed ID: 613575
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of renovascular hypertension: saralasin test versus renin determinations.
    Marks LS; Maxwell MH; Smith RB; Cahill PJ; Kaufman JJ
    J Urol; 1976 Oct; 116(4):406-9. PubMed ID: 1053323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical usefulness of saralasin in human hypertension (author's transl)].
    Fouchard M; Bichara M; Grüfeld JP; Barbanel C; Meyer P; Funck-Brentano JL
    Nouv Presse Med; 1978 Feb; 7(7):539-43. PubMed ID: 643579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic studies of infusions with [Sar 1, Val5, Ala8] angiotensin II (saralasin).
    Gless KH; Bönner G; Gram N; Mann JF; Helber A; Ganten D
    Klin Wochenschr; 1978; 56 Suppl 1():97-105. PubMed ID: 732257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saralasin infusion in the recognition of renovascular hypertension.
    Wilson HM; Wilson JP; Slaton PE; Foster JH; Liddle GW; Hollifield JW
    Ann Intern Med; 1977 Jul; 87(1):36-42. PubMed ID: 879617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hemodynamic effects of sar1-ala8-angiotensin in patients with renovascular hypertension (author's transl)].
    Philipp T; Zschierdrich H; Distler A
    Klin Wochenschr; 1977 Sep; 55(18):917-9. PubMed ID: 916618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with saralasin infusion in hypertensive patients.
    Tegtmeyer CJ; Latour EA; Vaughan ED; Ayers CR; Carey RM; Wellons HA
    Invest Radiol; 1977; 12(6):496-504. PubMed ID: 591250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. False-negative saralasin responses in renovascular hypertension.
    Stokes GS; MacCarthy EP; Frost GW; Sheil AG
    Br J Urol; 1979 Apr; 51(2):92-9. PubMed ID: 465980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of saralasin infusion on bilateral renal function in two-kidney, one-clip Goldblatt hypertensive rats.
    Huang WC; Ploth DW; Navar LG
    Clin Sci (Lond); 1982 Jun; 62(6):573-9. PubMed ID: 7083749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of saralasin in the recognition of angiotensinogenic hypertension.
    Streeten DH; Dalakos TG; Anderson GH
    Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of angiotensinogenic hypertension: the complementary roles of renal scintigraphy and the saralasin infusion test.
    McAfee JG; Thomas FD; Grossman Z; Streeten DH; Dailey E; Gagne G
    J Nucl Med; 1977 Jul; 18(7):669-75. PubMed ID: 874145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.
    Case DB; Wallace JM; Keim HJ; Weber MA; Drayer JI; White RP; Sealey JE; Laragh JH
    Am J Med; 1976 Nov; 61(5):790-6. PubMed ID: 185903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;
    Streeten DH; Anderson GH; Freiberg JM; Dalakos TG
    N Engl J Med; 1975 Mar; 292(13):657-62. PubMed ID: 235090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin blockade in renovascular hypertension: a controlled, prospective study.
    Marks LS; Maxwell MH; Gross C; Waks U; Kaufman JJ
    Br J Urol; 1977 Jun; 49(3):181-8. PubMed ID: 334316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saralasin infusion in renovascular and essential hypertension.
    Thien T; Hoefnagels WH
    Neth J Med; 1980; 23(2):68-73. PubMed ID: 6990282
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of age on diagnostic usefulness of stimulated plasma renin activity and saralasin test in detection of renovascular hypertension.
    Anderson GH; Springer J; Randall P; Streeten DH; Blakeman N
    Lancet; 1980 Oct; 2(8199):821-4. PubMed ID: 6107499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.